Overview

A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence

Status:
Completed
Trial end date:
1997-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to is to evaluate the safety and efficacy of OROS® oxybutynin chloride in patients being treated for urge urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
Phase:
Phase 3
Details
Lead Sponsor:
Alza Corporation, DE, USA
Treatments:
Mandelic Acids
Oxybutynin